You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,456,479


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,456,479
Title:Hydrophilic linkers and ligand-drug conjugates thereof
Abstract: Hydrophilic linkers are useful for linking drugs to cell-binding ligands in ligand-drug conjugates, such as antibody-drug conjugates. The ligand-drug conjugate includes a cell-binding ligand capable of binding to a particular cell population, and a drug connected to the ligand by a hydrophilic linker. The hydrophilic linker includes one or more hydrophilic groups that render the linker hydrophilic. The hydrophilic linker may also include functional groups at the two termini for coupling to the drug and the cell-binding ligand respectively.
Inventor(s): Sun; Sanxing (Hangzhou, CN), Zhao; Robert Yongxin (Hangzhou, CN), Li; Xing (Hangzhou, CN), Guo; Huihui (Hangzhou, CN), Jia; Junxiang (Hangzhou, CN), Xie; Hongsheng (Hangzhou, CN), Zhou; Xiaomai (Hangzhou, CN), Huang; Yuanyuan (Hangzhou, CN), Yang; Qingliang (Hangzhou, CN), Zhuo; Xiaotao (Hangzhou, CN), Ye; Hangbo (Hangzhou, CN), Gai; Shun (Hangzhou, CN), Qu; Lan (Hangzhou, CN), Li; Wenjun (Hangzhou, CN), Lin; Chen (Hangzhou, CN)
Assignee: HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)
Application Number:15/558,917
Patent Claims:1. A ligand-drug conjugate of formula (2): ##STR00066## wherein: D represents a cytotoxic drug; L represents a cell-binding ligand; V represents a polar or charged group selected from the group consisting of ##STR00067## (sulfonamides) ##STR00068## (sulfonic acids), ##STR00069## (sulfamic acids), wherein R is H, C.sub.1.about.C.sub.8 alkyl, or NH.sub.2; Q is CH or N; Z is NH, NH--(CH.sub.2).sub.m, or N(CH.sub.3)(CH.sub.2).sub.m, wherein m is an integer from 1 to 5, and "" is a site of attachment; U' represents a covalent linkage selected from the group consisting of a disulfide linkage, a thioether linkage, a thioester linkage, an amide linkage, an ester linkage, a carbon-nitrogen linkage, a carbon-carbon linkage, a hydrazine linkage, a hydrazide linkage, a hydrazone linkage, an ether linkage, a carbamate linkage, and a carbonate linkage; W' represents a covalent linkage selected from the group consisting of an amide linkage, a carbamate linkage, a urea linkage, a disulfide linkage, a thioether linkage, a thiocarbamate linkage, a dithiocarbamate linkage, and a thioester linkage; X represents a component composed of one, two, or three methylene units optionally substituted with an alkyl, halo, hydroxyl, or alkoxy group; Y represents a component composed of one, two, or three methylene units optionally substituted with an alkyl, halo, hydroxyl, or alkoxy group; n is an integer from 1 to 100, provided that when n>1, values of each V, X, and Y in the repeating, brackets of Formula (2) are independent and do not have to be identical.

2. The conjugate of claim 1, wherein the cell-binding ligand is an antibody, a single chain antibody, an antibody fragment that selectively binds to a target cell, a monoclonal antibody, a single chain monoclonal antibody, a single chain monoclonal antibody fragment that selectively binds to a target cell, a resurfaced monoclonal antibody, a resurfaced single chain monoclonal antibody, a resurfaced monoclonal antibody fragment that selectively binds to a target cell, a chimeric antibody, a single chain chimeric antibody, a single chain chimeric antibody fragment that selectively binds to a target cell, a humanized monoclonal antibody, a humanized single chain monoclonal antibody, a humanized monoclonal antibody fragment that selectively binds to a target cell, an antibody mimic, a lymphokine, a hormone, or a growth factor.

3. The conjugate of claim 2, wherein the antibody: s trastuzumab, pertuzumab, rituximab, ofatumumab, tositumomab, ibritumomab, oregovomab, edrecolomab, cetuximab, panitumumab, nimotuzumab, brentuximab, gemtuzumab, huMy9-6, etaracizumab, alemtuzumab, epratuzumab, labetuzumab, bivatuzumab, sibrotuzumab, huB4, huC242, huN901, daratumumab, DS6, cixutumumab, 3B7, ONTO 95, or 1-84.

4. The conjugate of claim 1, wherein the cell-binding ligand binds to tumor cells expressing tumor associated antigens, epidermal growth factor receptors (EGFR), astrin-releasing peptide receptor (GRPR), bone morphogenetic protein receptor IB (BMPR1B), folate receptor, metalloreductase STEAP1, sodium-dependent phosphate transport protein 2B (Napi3b or SLC34A2), brevican, ephrin receptors (Ephs), prostate stem cell antigen (PSCA), B cell activating factor of the TNF family receptor (BAFF-R), C--X--C chemokine receptor type 5 (CXC-R5, CD185, or BLR1), HLA class II histocompatibility antigen-DO beta chain (HLA-DOB), P2X purinoceptor 5 (P2X5 or P2RX5), transferrin receptors (TfR), hormone receptors, growth-hormone-releasing hormone receptor (GHRHR), epithelial cell adhesion molecule, gangliosides, FMS-like tyrosine kinase 3 (FLT3), prostate-specific membrane antigen (PSMA), mucin 1 (MUC1), mucin 16 (MUC16 or CA-125), six transmembrane epithelial antigen of prostate (STEAP), carcinoembryonic antigen (CEA), decay accelerating factor (DAF or CD55), folate receptors, mesothelin, cryptic family protein 1B (Cripto), integrins, growth factors, transferrins receptors, transport proteins, homing receptors, endothelial cell--linked antigens, IGF-IR, CanAg, C242 antigens, or CD molecules.

5. The conjugate of claim 1, wherein the cytotoxic drug is a maytansinoid, dolastatin, an auristatin, a calicheamicin, a tubulysin, a mitomycin, an actinomycin, a camptothecin, a vinca alkaloid, an anthracycline, a duocarmycin, or a pyrrolo[2,1-c][1,4]benzodiazepines (PBD).

6. The conjugate of claim 1, wherein the cytotoxic drug is DM1.

7. The conjugate of claim 1, wherein the cytotoxic drug is DM4.

8. The conjugate of claim 1, wherein the cytotoxic drug is MMAF.

9. The conjugate of claim 1, wherein V is --N(SO.sub.2OH)--.

10. The conjugate of claim 1, wherein n is an integer from 1 to 50.

11. The conjugate of claim 1, wherein n is an integer from 1 to 10.

12. The conjugate of claim 1, wherein n is 1.

13. The conjugate of claim 1, which is a compound of Compound (52)-(55), or (63): ##STR00070##

14. A ligand-drug conjugate of formula (2): ##STR00071## wherein: D represents a cytotoxic drug; L represents a cell-binding ligand; V represents a polar or charged group selected from the group consisting of ##STR00072## (phosphonates), ##STR00073## (phosphoric acids), ##STR00074## (phosphoramidic acids), ##STR00075## (phosphorodiamidic acids), and ##STR00076## (phosphoric triamides), wherein R is H or C.sub.1.about.C.sub.8 alkyl; Q is CH or N L is NH, NH--(CH.sub.2).sub.m, or N(CH.sub.3)(CH.sub.2).sub.m, wherein m is an integer from 1 to 5, and "" is a site of attachment; U' represents a covalent linkage selected from the group consisting of a disulfide linkage, a thioether linkage, a thioester linkage, an amide linkage, an ester linkage, a carbon-nitrogen linkage, a carbon-carbon linkage, a hydrazine linkage, a hydrazide linkage, a hydrazone linkage, an ether linkage, a carbamate linkage, and a carbonate linkage; W' represents a covalent linkage selected from the group consisting of an amide linkage, a carbamate linkage, a urea linkage, a disulfide linkage, a thioether linkage, a thiocarbamate linkage, a dithiocarbamate linkage, and a thioester linkage; X represents a component composed of one, two, or three methylene units optionally substituted with an alkyl, halo, hydroxyl, alkoxy group; Y represents a component composed of one, two, or three methylene units optionally substituted with an alkyl, halo, hydroxyl, or alkoxy group; n is an integer from 1 to 100, provided that when n>1, values of each V, X, and Y in the repeating brackets of Formula (2) are independent and do not have to be identical.

15. The conjugate of claim 14, wherein the cell-binding ligand is an antibody, a single chain antibody, an antibody fragment that selectively binds to a target cell, a monoclonal antibody, a single chain monoclonal antibody, a single chain monoclonal antibody fragment that selectively binds to a target cell, a resurfaced monoclonal antibody, a resurfaced single chain monoclonal antibody, a resurfaced monoclonal antibody fragment that selectively binds to a target cell, a chimeric antibody, a single chain chimeric antibody, a single chain chimeric antibody fragment that selectively binds to a target cell, a humanized monoclonal antibody, a humanized single chain monoclonal antibody, a humanized monoclonal antibody fragment that selectively binds to a target cell, an antibody mimic, a lymphokine, a hormone, or a growth factor.

16. The conjugate of claim 15, wherein the antibody is trastuzumab, pertuzumab, rituximab, ofatumumab, tositumomab, ibritumomab, oregovomab, edrecolomab, cetuximab panitumumab, nimotuzumab, brentuximab, gemtuzumab, huMy9-6, etaracizumab, alemtuzumab, epratuzumab, labetuzumab, bivatuzumab, sibrotuzumab, huB4, huC242, huN901, daratumumab, DS6, cixutumumab, 3B7, CNTO 95, or B-B4.

17. The conjugate of claim 14, wherein the cell-binding ligand binds to tumor cells expressing tumor associated antigens, epidermal growth factor receptors (EGFR), astrin-releasing peptide receptor (GRPR), hone morphogenetic protein receptor I B (BMPR1B), folate receptor, metalloreductase STEAP1, sodium-dependent phosphate transport protein 2B (Napi3b or SLC34A2), brevican, ephrin receptors (Ephs), prostate stem cell antigen (PSCA), B cell activating factor of the TNF family receptor (BAFF-R), C--X--C chemokine receptor type 5 (CXC-R5, CD185, or BLR1), MA class II histocompatibility antigen-DO beta chain (HLA-DOB), P2X purinoceptor 5 (P2X5 or P2RX5), transferrin receptors (TfR), hormone receptors, growth-hormone-releasing hormone receptor (GHRHR), epithelial cell adhesion molecule, gangliosides, FMS-like tyrosine kinase 3 (FLT3), prostate-specific membrane antigen (PSMA), mucin 1 (MUC1), mucin 16 (MUC16 or CA-125), six transmembrane epithelial antigen of prostate (STEAP), carcinoembryonic antigen (CEA), decay accelerating factor (DAF or CD55), folate receptors, mesothelin, cryptic family protein 1B (Cripto), integrins, growth factors, transferrins receptors, transport proteins, homing receptors, endothelial cell-linked antigens, IGF-IR, CanAg, C242 antigens, or CD molecules.

18. The conjugate of claim 14, wherein the cytotoxic drug is a maytansinoid, a dolastatin, an auristatin, a calicheamicin, a tubulysin, a mitomycin, an actinomycin, camptothecin, vinca alkaloid, an anthracycline, a duocarmycin, or a pyrrolo[2,1-c][1,4]benzodiazepines (PBD).

19. The conjugate of claim 14, wherein the cytotoxic drug is DM1.

20. The conjugate of claim 14, wherein the cytotoxic drug is M14.

21. The conjugate of claim 14, wherein the cytotoxic drug is MMAF.

22. The conjugate of claim 14, wherein V is --N[PO(OH).sub.2]--.

23. The conjugate of claim 14, wherein n is an integer from 1 to 50.

24. The conjugate of claim 14, wherein n is an integer from 1 to 10.

25. The conjugate of claim 14, wherein n is 1.

26. The conjugate of claim 14, which is a compound of compound (56)-(59), (61) or (62): ##STR00077##

Details for Patent 10,456,479

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2039-10-29
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2039-10-29
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2039-10-29
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2039-10-29
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 11/14/2014 ⤷  Try a Trial 2039-10-29
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 10/12/2004 ⤷  Try a Trial 2039-10-29
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2039-10-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.